Abstract

A total of 80 patients were equally randomized to receive a single dose of 6.5% tioconazole ointment or a 3-day course of 100-mg clotrimazole vaginal tablets for the treatment of vulvovaginal candidiasis. Of the 32 evaluable patients treated with tioconazole, 27 (84%) remained asymptomatic 4 weeks posttreatment, compared with 28 of 33 patients (85%) treated with clotrimazole. A total of 34 patients in each group could be evaluated for mycological response based on culture results 1 and 4 weeks after treatment. Twenty patients (59%) who received tioconazole and twenty-one patients (62%) who received clotrimazole remained culture negative 4 weeks after therapy. Of 40 patients who received tioconazole, 12 (30%) experienced local irritation or itching, compared with 2 of 40 patients (5%) treated with clotrimazole (P less than 0.01). Single-dose tioconazole ointment was as effective as a 3-day course of clotrimazole tablets, but significantly more patients in the tioconazole-treated group experienced local side effects.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

1. Balmer J. A. Three-day therapy of vulvovaginal candidiasis with econazole: a multicentric study comprising 996 cases. Am J Obstet Gynecol. 1976 Oct 15;126(4):436–441. doi: 10.1016/0002-9378(76)90633-5. [DOI] [PubMed] [Google Scholar]
2. Cohen L. Single dose treatment of vaginal candidosis: comparison of clotrimazole and isoconazole. Br J Vener Dis. 1984 Feb;60(1):42–44. doi: 10.1136/sti.60.1.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
3. Gabriel G., Thin R. N. Clotrimazole and econazole in the treatment of vaginal candidosis. A single-blind comparison. Br J Vener Dis. 1983 Feb;59(1):56–58. doi: 10.1136/sti.59.1.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
4. García-Tamayo J., Castillo G., Martínez A. J. Human genital candidiasis: histochemistry, scanning and transmission electron microscopy. Acta Cytol. 1982 Jan-Feb;26(1):7–14. [PubMed] [Google Scholar]
5. Hilton A. L., Warnock D. W. Vaginal candidiasis and the role of the digestive tract as a source of infection. Br J Obstet Gynaecol. 1975 Nov;82(11):922–926. doi: 10.1111/j.1471-0528.1975.tb00599.x. [DOI] [PubMed] [Google Scholar]
6. Houang E. T., Lawrence A. G. Systemic absorption and persistence of tioconazole in vaginal fluid after insertion of a single 300-mg tioconazole ovule. Antimicrob Agents Chemother. 1985 Jun;27(6):964–965. doi: 10.1128/aac.27.6.964. [DOI] [PMC free article] [PubMed] [Google Scholar]
7. Hurley R. Recurrent Candida infection. Clin Obstet Gynaecol. 1981 Apr;8(1):209–214. [PubMed] [Google Scholar]
8. Jevons S., Gymer G. E., Brammer K. W., Cox D. A., Leeming M. R. Antifungal activity of tioconazole (UK-20,349), a new imidazole derivative. Antimicrob Agents Chemother. 1979 Apr;15(4):597–602. doi: 10.1128/aac.15.4.597. [DOI] [PMC free article] [PubMed] [Google Scholar]
9. Lefler E., Stevens D. A. Inhibition and killing of Candida albicans in vitro by five imidazoles in clinical use. Antimicrob Agents Chemother. 1984 Apr;25(4):450–454. doi: 10.1128/aac.25.4.450. [DOI] [PMC free article] [PubMed] [Google Scholar]
10. Masterton G., Henderson J., Napier I. R., Moffet M. Six-day clotrimazole therapy in vaginal candidosis. Curr Med Res Opin. 1975;3(2):83–88. doi: 10.1185/03007997509113652. [DOI] [PubMed] [Google Scholar]
11. Masterton G., Napier I. R., Henderson J. N., Roberts J. E. Three-day clotrimazole treatment in candidal vulvovaginitis. Br J Vener Dis. 1977 Apr;53(2):126–128. doi: 10.1136/sti.53.2.126. [DOI] [PMC free article] [PubMed] [Google Scholar]
12. Miles M. R., Olsen L., Rogers A. Recurrent vaginal candidiasis. Importance of an intestinal reservoir. JAMA. 1977 Oct 24;238(17):1836–1837. doi: 10.1001/jama.238.17.1836. [DOI] [PubMed] [Google Scholar]
13. Milne J. D., Warnock D. W. Effect of simultaneous oral and vaginal treatment on the rate of cure and relapse in vaginal candidosis. Br J Vener Dis. 1979 Oct;55(5):362–365. doi: 10.1136/sti.55.5.362. [DOI] [PMC free article] [PubMed] [Google Scholar]
14. Milsom I., Forssman L. Treatment of vaginal candidosis with a single 500-mg clotrimazole pessary. Br J Vener Dis. 1982 Apr;58(2):124–126. doi: 10.1136/sti.58.2.124. [DOI] [PMC free article] [PubMed] [Google Scholar]
15. Odds F. C. Cure and relapse with antifungal therapy. Proc R Soc Med. 1977;70 (Suppl 4):24–32. [PMC free article] [PubMed] [Google Scholar]
16. Odds F. C. Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance. J Antimicrob Chemother. 1980 Nov;6(6):749–761. doi: 10.1093/jac/6.6.749. [DOI] [PubMed] [Google Scholar]
17. Oriel J. D., Partridge B. M., Denny M. J., Coleman J. C. Genital yeast infections. Br Med J. 1972 Dec 30;4(5843):761–764. doi: 10.1136/bmj.4.5843.761. [DOI] [PMC free article] [PubMed] [Google Scholar]
18. Robertson W. H. A concentrated therapeutic regimen for vulvovaginal candidiasis. JAMA. 1980 Dec 5;244(22):2549–2550. [PubMed] [Google Scholar]
19. Robertson W. H. Vulvovaginal candidiasis treated with clotrimazole cream in seven days compared with fourteen-day treatment with miconazole cream. Am J Obstet Gynecol. 1978 Oct 1;132(3):321–323. doi: 10.1016/0002-9378(78)90900-6. [DOI] [PubMed] [Google Scholar]
20. Sobel J. D. Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstet Gynecol. 1985 Mar;65(3):435–440. [PubMed] [Google Scholar]
21. Warnock D. W., Speller C. D., Milne J. D., Hilton A. L., Kershaw P. I. Epidemiological investigation of patients with vulvovaginal candidosis. Application of a resistogram method for strain differentiation of Candida albicans. Br J Vener Dis. 1979 Oct;55(5):357–361. doi: 10.1136/sti.55.5.357. [DOI] [PMC free article] [PubMed] [Google Scholar]